Dual-targeting delivery system for bone cancer: synthesis and preliminary biological evaluation

References

• Alpizar YA, Chain B, Collins MK, Greenwood J, Katz D, Stauss HJ, Mitchison NA. (2011). Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies. Cancer Immunol Immunother 60:1127–1135.
   Google Scholar
• Barczyk M, Carracedo S, Gullberg D. (2010). Integrins. Cell Tissue Res 339:269–280.
   PubMed Web of Science ®Google Scholar
• Byrne JD, Betancourt T, Brannon-Peppas L. (2008). Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 60:1615–1626.
   PubMed Web of Science ®Google Scholar
• He G, Guo L, Ma LF. (2006). Synthesis of novel dendrimers containing amino acids and peptides. Chinese Chem Lett 17:289–292.
   Web of Science ®Google Scholar
• Jackson KE, Pham JS, Kwek M, De Silva NS, Allen SM, Goodman CD, McFadden GI, de Pouplana LR, Ralph SA. (2012). Dual targeting of aminoacyl-tRNA synthetases to the apicoplast and cytosol in Plasmodium falciparum. Int J Parasitol 42:177–186.
   PubMed Web of Science ®Google Scholar
• Lu YJ, Wei KC, Ma CC, Yang SY, Chen JP. (2012). Dual targeted delivery of doxorubicin to cancer cells using folate-conjugated magnetic multi-walled carbon nanotubes. Colloids Surf B Biointerfaces 89:1–9.
   PubMed Web of Science ®Google Scholar
• Miller K, Eldar-Boock A, Polyak D, Segal E, Benayoun L, Shaked Y, Satchi-Fainaro R. (2011). Antiangiogenic Antitumor Activity of HPMA Copolymer-Paclitaxel-Alendronate Conjugate on Breast Cancer Bone Metastasis Mouse Model. Mol pharm 8:1052–1062.
   PubMed Web of Science ®Google Scholar
• Miller K, Erez R, Segal E, Shabat D, Satchi-Fainaro R. (2009). Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew Chem Int Ed Engl 48:2949–2954.
   PubMed Web of Science ®Google Scholar
• Murphy EA, Majeti BK, Barnes LA, Makale M, Weis SM, Lutu-Fuga K, Wrasidlo W, Cheresh DA. (2008). Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci USA 105:9343–9348.
   PubMed Web of Science ®Google Scholar
• Ouyang L, He D, Zhang J, He G, Jiang B, Wang Q, Chen Z, Pan J, Li Y, Guo L. (2011). Selective bone targeting 5-fluorouracil prodrugs: synthesis and preliminary biological evaluation. Bioorg Med Chem 19:3750–3756.
   PubMed Web of Science ®Google Scholar
• Ouyang L, Huang WC, He G, Guo L. (2009). Bone targeting prodrugs based on peptide dendrimers, synthesis and hydroxyapatite binding in vitro. Lett Org Chem 6:272–277.
   Web of Science ®Google Scholar
• Ouyang L, Zhang J, Pan J, Yan L, Guo L. (2009). Synthesis and preliminary evaluation in vitro of novel naproxen-dendritic peptide conjugates. Drug Deliv 16:348–356.
   PubMed Web of Science ®Google Scholar
• Pan JZ, Wen M, Yin DQ, Jiang B, He DS, Guo L. (2012). Design and synthesis of novel amphiphilic Janus dendrimers for bone-targeted drug delivery. Tetrahedron 68, 2943–2949.
   Web of Science ®Google Scholar
• Petkau K, Kaeser A, Fischer I, Brunsveld L, Schenning AP. (2011). Pre- and postfunctionalized self-assembled p-conjugated fluorescent organic nanoparticles for dual targeting. J Am Chem Soc 133:17063–17071.
   PubMed Web of Science ®Google Scholar
• Ray A, Larson N, Pike DB, Grüner M, Naik S, Bauer H, Malugin A, Greish K, Ghandehari H. (2011). Comparison of active and passive targeting of docetaxel for prostate cancer therapy by HPMA copolymer-RGDfK conjugates. Mol Pharm 8:1090–1099.
   PubMed Web of Science ®Google Scholar
• Shao H, Gao C, Tang H, Zhang H, Roberts LR, Hylander BL, Repasky EA, Ma WW, Qiu J, Adjei AA, Dy GK, Yu C. (2012). Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo. J Hepatol 56:176–183.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Yokogawa K, Sakura N, Nomura M, Kobayashi S, Miyamoto K. (2008). Bone-targeting of quinolones conjugated with an acidic oligopeptide. Pharm Res 25:2881–2888.
   PubMed Web of Science ®Google Scholar
• Takahashi-Nishioka T, Yokogawa K, Tomatsu S, Nomura M, Kobayashi S, Miyamoto K. (2008). Targeted drug delivery to bone: pharmacokinetic and pharmacological properties of acidic oligopeptide-tagged drugs. Curr Drug Discov Technol 5:39–48.
   PubMedGoogle Scholar
• Tang X, Zhang P, Ye H, Zhang C, Shen W, Ping Q. (2008). Water-soluble gambogic acid PEGylated prodrugs: synthesis, characterization, physicochemical properties and in vitro hydrolysis. Pharmazie 63:711–717.
   PubMed Web of Science ®Google Scholar
• Temming K, Meyer DL, Zabinski R, Senter PD, Poelstra K, Molema G, Kok RJ. (2007). Improved efficacy of alphavbeta3-targeted albumin conjugates by conjugation of a novel auristatin derivative. Mol Pharm 4:686–694.
   PubMed Web of Science ®Google Scholar
• Teti A, Migliaccio S, Baron R. (2002). The role of the alphaVbeta3 integrin in the development of osteolytic bone metastases: a pharmacological target for alternative therapy? Calcif Tissue Int 71:293–299.
   PubMed Web of Science ®Google Scholar
• Wang D, Miller S, Sima M, Kopecková P, Kopecek J. (2003). Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems. Bioconjug Chem 14:853–859.
   PubMed Web of Science ®Google Scholar
• Xu Q, Liu Y, Su S, Li W, Chen C, Wu Y. (2012). Anti-tumor activity of paclitaxel through dual-targeting carrier of cyclic RGD and transferrin conjugated hyperbranched copolymer nanoparticles. Biomaterials 33:1627–1639.
   PubMed Web of Science ®Google Scholar
• Yogev O, Naamati A, Pines O. (2011). Fumarase: a paradigm of dual targeting and dual localized functions. FEBS J 278:4230–4242.
   PubMed Web of Science ®Google Scholar